tiprankstipranks
Advertisement
Advertisement
Analyst Reiterates Buy on Curis, Maintains $17 Price Target Amid Progress in TakeAim CLL Trial and Nasdaq Compliance Steps
PremiumRatingsAnalyst Reiterates Buy on Curis, Maintains $17 Price Target Amid Progress in TakeAim CLL Trial and Nasdaq Compliance Steps
16d ago
Curis announces eleven active clinical sites in TakeAim CLL study
Premium
The Fly
Curis announces eleven active clinical sites in TakeAim CLL study
16d ago
Curis Shareholders Approve Flexible Reverse Stock Split Authorization
Premium
Company Announcements
Curis Shareholders Approve Flexible Reverse Stock Split Authorization
17d ago
Why Is Vanguard Total Stock Market (VTI) ETF Up Today, 5/13/26?
PremiumMarket NewsWhy Is Vanguard Total Stock Market (VTI) ETF Up Today, 5/13/26?
2M ago
Curis Reaffirmed at Buy as Analyst Maintains $5 Price Target on Emavusertib Clinical Catalysts in CLL and PCNSL
Premium
Ratings
Curis Reaffirmed at Buy as Analyst Maintains $5 Price Target on Emavusertib Clinical Catalysts in CLL and PCNSL
2M ago
Curis Buy Rating Reiterated as Analyst Highlights Dual-Blockade Progress and Clinical Catalysts; $17 Price Target Maintained
Premium
Ratings
Curis Buy Rating Reiterated as Analyst Highlights Dual-Blockade Progress and Clinical Catalysts; $17 Price Target Maintained
2M ago
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/8/26?
PremiumMarket NewsWhy Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/8/26?
2M ago
Why Is Vanguard Total Stock Market (VTI) ETF Up Today, 5/7/26?
Premium
Market News
Why Is Vanguard Total Stock Market (VTI) ETF Up Today, 5/7/26?
2M ago
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/6/26?
Premium
Market News
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/6/26?
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100